Product Information
PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) is a brand product labeled by Pfizer Inc., priced at $133.9671 per EA under NDC 00069545011. Its NADAC has been published 35 times since Feb 4, 2026.
FDA first approved this application on May 25, 2023.
Manufacturer
Pfizer Inc.NDC
00069545011
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA217188FDA Approved
5/25/2023
On Market Since
1/5/2026
Price Statistics
The NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has been published 35 times since Feb 4, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $133.9671 per EA |
|---|---|
| All-time high | $134.1575 (Jun 10, 2026) |
| All-time low | $133.5413 (Jun 17, 2026) |
| 52-week high | $134.1575 |
| 52-week low | $133.5413 |
| Median price | $134.1575 |
| Average price | $133.9610 |
| Largest weekly change | -0.5% (Jun 17, 2026) |
| Weeks tracked | 35 |
| Tracking since | Feb 4, 2026 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nirmatrelvir and ritonavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?
The current National Average Drug Acquisition Cost (NADAC) for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE), manufactured by Pfizer Inc., is $133.9671 per EA (NDC 00069545011), effective Sep 30, 2026.
How has the price of PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) changed over time?
Over the history we have for it, the NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has held within roughly two percent of its current level. It has been tracked across 35 weekly CMS publications since Feb 4, 2026.
What are the highest and lowest recorded NADAC prices for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?
Since Feb 4, 2026, the NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has ranged from a low of $133.5413 (Jun 17, 2026) to a high of $134.1575 (Jun 10, 2026), with a median of $134.1575 per EA.
Are there cheaper alternatives to PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PAXLOVID 300-100 MG DOSE PACK, is $49.2371 per EA — about 63% below PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE).
Who manufactures PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?
PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) (NDC 00069545011) is labeled by Pfizer Inc., and CMS classifies it as a brand product.